- Home
- HPK vs EVMN Comparison
HPK vs EVMN Comparison
Compare HPK & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | EVMN |
|---|---|---|
| Founded | 2019 | 2020 |
| Country | United States | United States |
| Employees | 50 | 48 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 907.3M | 869.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HPK | EVMN |
|---|---|---|
| Price | $6.70 | $12.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $12.00 | ★ $43.88 |
| AVG Volume (30 Days) | 697.3K | ★ 1.2M |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $12.51 |
| 52 Week High | $10.41 | $33.20 |
Technical Indicators
Market Signals| Indicator | HPK | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 29.11 |
| Support Level | $6.55 | N/A |
| Resistance Level | $7.26 | $20.37 |
| Average True Range (ATR) | 0.47 | 1.75 |
| MACD | -0.12 | -0.97 |
| Stochastic Oscillator | 15.66 | 3.37 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.